(Q63838613)
Statements
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis (English)
0 references
January 2013
0 references
November 2013
0 references
32
0 references
18 year
0 references